NCT01579903 - Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions

Hemophilia A

Interventions

DRUG

moroctocog alfa (AF-CC)

Treatment A: 3000 IU moroctocog alfa (AF-CC) dual chamber syringe (including diluent); Treatment B: 1000 IU + 2000 IU moroctocog alfa (AF-CC) vials and separate diluent syringes

DRUG

moroctocog alfa (AF-CC)

Treatment B: 1000 IU + 2000 IU moroctocog alfa (AF-CC) vials and separate diluent syringes; Treatment A: 3000 IU moroctocog alfa (AF-CC) dual chamber syringe (including diluent)

Trial Locations (3)

1083

Pfizer Investigational Site, Budapest

1612

Pfizer Investigational Site, Sofia

NW3 2QG

Pfizer Investigational Site, London